Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Critical Therapeutics has received a $5 million milestone payment from Dey LP, a subsidiary of Mylan, as part of a co-promotion agreement between the companies for Zyflo CR extended-release tablets, a twice-daily formulation for the prophylaxis and chronic treatment of asthma in adults aged 12 and older.
Subscribe to our email newsletter
With this payment, Critical Therapeutics has now received a total of $12 million from Dey as part of the companies’ co-promotion agreement. Critical Therapeutics received $3 million from Dey upon signing the co-promotion agreement in the first quarter of 2007 and $4 million upon the FDA’s approval of Zyflo CR in the second quarter of 2007.
Frank Thomas, president and CEO of Critical Therapeutics, said: “We are seeing steady growth in new prescriptions of Zyflo CR and are encouraged by the progress we have achieved since the launch of Zyflo CR in late September. Critical Therapeutics and Dey’s combined sales forces of 240 representatives are promoting Zyflo CR to approximately 18,000 allergists, pulmonologists and primary care physicians across the country.”